Abbott Yields To Brazil Pressure, Avoids Compulsory License On Kaletra

Law360, New York (July 10, 2005, 12:00 AM EDT) -- In a last-minute compromise that averted a compulsory license, U.S. drug maker Abbott Laboratories agreed Friday to lower the price the Brazilian government pays for its AIDS drug Kaletra.

Brazil had threatened to break Abbott's patent on Kaletra and manufacture a generic version in its state-owned drug plant in Rio de Janeiro if it didn't get a price break from Abbott.

The agreement, reached after 10 days of negotiations, calls for Abbott Laboratories to significantly reduce its price for the drug Kaletra over the next six...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.